52 related articles for article (PubMed ID: 31088401)
1. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
Brenner A; Zuniga R; Sun JD; Floyd J; Hart CP; Kroll S; Fichtel L; Cavazos D; Caflisch L; Gruslova A; Huang S; Liu Y; Lodi A; Tiziani S
Neuro Oncol; 2018 Aug; 20(9):1231-1239. PubMed ID: 29415215
[TBL] [Abstract][Full Text] [Related]
2. The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme.
Witte HM; Riecke A; Steinestel K; Schulz C; Küchler J; Gebauer N; Tronnier V; Leppert J
Br J Neurosurg; 2024 Apr; 38(2):404-410. PubMed ID: 33590799
[TBL] [Abstract][Full Text] [Related]
3. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranai Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
Brain Tumor Pathol; 2024 Apr; 41(2):61-72. PubMed ID: 38619734
[TBL] [Abstract][Full Text] [Related]
4. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence.
Christ SM; Youssef G; Tanguturi SK; Cagney D; Shi D; McFaline-Figueroa JR; Chukwueke U; Lee EQ; Hertler C; Andratschke N; Weller M; Reardon DA; Haas-Kogan D; Guckenberger M; Wen PY; Rahman R
Clin Transl Radiat Oncol; 2024 Jan; 44():100697. PubMed ID: 38046107
[TBL] [Abstract][Full Text] [Related]
5. Survival effects of a strategy favoring second-line multimodal treatment compared to supportive care in glioblastoma patients at first progression.
Stavrinou P; Kalyvas A; Grau S; Hamisch C; Galldiks N; Katsigiannis S; Kabbasch C; Timmer M; Goldbrunner R; Stranjalis G
J Neurosurg; 2018 Nov; 131(4):1136-1141. PubMed ID: 30544353
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Jeon H; Byun J; Kang H; Kim K; Lee E; Kim JH; Hong CK; Song SW; Kim YH; Chong S; Kim JH; Nam SJ; Park JE; Lee S
J Transl Med; 2023 Feb; 21(1):69. PubMed ID: 36732815
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
[TBL] [Abstract][Full Text] [Related]
8. Characterization of serial hyperpolarized
Autry AW; Gordon JW; Chen HY; LaFontaine M; Bok R; Van Criekinge M; Slater JB; Carvajal L; Villanueva-Meyer JE; Chang SM; Clarke JL; Lupo JM; Xu D; Larson PEZ; Vigneron DB; Li Y
Neuroimage Clin; 2020; 27():102323. PubMed ID: 32623139
[TBL] [Abstract][Full Text] [Related]
9. Epithelioid glioblastoma presenting as multicentric glioma: A case report and review of the literature.
Kohno D; Inoue A; Fukushima M; Aki T; Matsumoto S; Suehiro S; Nishikawa M; Ozaki S; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
Surg Neurol Int; 2020; 11():8. PubMed ID: 31966927
[TBL] [Abstract][Full Text] [Related]
10. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.
Back M; Gzell CE; Kastelan M; Guo L; Wheeler HR
Neurooncol Pract; 2015 Mar; 2(1):48-53. PubMed ID: 26034641
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
Tipping M; Eickhoff J; Ian Robins H
J Clin Neurosci; 2017 Oct; 44():101-106. PubMed ID: 28711289
[TBL] [Abstract][Full Text] [Related]
12. The role of bevacizumab in the treatment of glioblastoma.
Diaz RJ; Ali S; Qadir MG; De La Fuente MI; Ivan ME; Komotar RJ
J Neurooncol; 2017 Jul; 133(3):455-467. PubMed ID: 28527008
[TBL] [Abstract][Full Text] [Related]
13. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.
Cuncannon M; Wong M; Jayamanne D; Guo L; Cove N; Wheeler H; Back M
BMC Cancer; 2019 May; 19(1):445. PubMed ID: 31088401
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]